Antiproliferative miR-212-5p: Promising RNA therapy for pulmonary hypertension.
作者信息
Perez-Vizcaino Francisco, Mondejar-Parreño Gema
机构信息
Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain.
出版信息
Mol Ther Nucleic Acids. 2022 Aug 27;29:689-690. doi: 10.1016/j.omtn.2022.08.015. eCollection 2022 Sep 13.
Abstract
摘要
相似文献
1
Antiproliferative miR-212-5p: Promising RNA therapy for pulmonary hypertension.抗增殖性miR-212-5p：肺动脉高压的有前景的RNA疗法。
Mol Ther Nucleic Acids. 2022 Aug 27;29:689-690. doi: 10.1016/j.omtn.2022.08.015. eCollection 2022 Sep 13.
2
CircGSAP regulates the cell cycle of pulmonary microvascular endothelial cells via the miR-942-5p sponge in pulmonary hypertension.环状GSAP通过作为肺动脉高压中miR-942-5p的海绵体来调节肺微血管内皮细胞的细胞周期。
Front Cell Dev Biol. 2022 Aug 11;10:967708. doi: 10.3389/fcell.2022.967708. eCollection 2022.
3
Role of miR-21-5p/FilGAP axis in estradiol alleviating the progression of monocrotaline-induced pulmonary hypertension.miR-21-5p/FilGAP 轴在雌二醇缓解野百合碱诱导的肺动脉高压进展中的作用。
Animal Model Exp Med. 2022 Sep;5(3):217-226. doi: 10.1002/ame2.12253. Epub 2022 Jun 17.
4
Circular RNA Sirtuin1 represses pulmonary artery smooth muscle cell proliferation, migration and autophagy to ameliorate pulmonary hypertension via targeting microRNA-145-5p/protein kinase-B3 axis.环状RNA沉默调节蛋白1通过靶向微小RNA-145-5p/蛋白激酶B3轴抑制肺动脉平滑肌细胞增殖、迁移和自噬，从而改善肺动脉高压。
Bioengineered. 2022 Apr;13(4):8759-8771. doi: 10.1080/21655979.2022.2036302.
5
MiR-18a-5p contributes to enhanced proliferation and migration of PASMCs via targeting Notch2 in pulmonary arterial hypertension.miR-18a-5p 通过靶向 Notch2 促进肺动脉平滑肌细胞的增殖和迁移，从而导致肺动脉高压。
Life Sci. 2020 Sep 15;257:117919. doi: 10.1016/j.lfs.2020.117919. Epub 2020 Jun 22.
6
Dysregulation of miR-135a-5p promotes the development of rat pulmonary arterial hypertension in vivo and in vitro.miR-135a-5p 的失调促进了大鼠肺动脉高压在体和体外的发展。
Acta Pharmacol Sin. 2019 Apr;40(4):477-485. doi: 10.1038/s41401-018-0076-9. Epub 2018 Jul 23.
7
miR-190a-5p participates in the regulation of hypoxia-induced pulmonary hypertension by targeting KLF15 and can serve as a biomarker of diagnosis and prognosis in chronic obstructive pulmonary disease complicated with pulmonary hypertension.微小RNA-190a-5p通过靶向KLF15参与低氧诱导的肺动脉高压的调控，并可作为慢性阻塞性肺疾病合并肺动脉高压的诊断和预后生物标志物。
Int J Chron Obstruct Pulmon Dis. 2018 Nov 20;13:3777-3790. doi: 10.2147/COPD.S182504. eCollection 2018.
8
MicroRNA-140-5p targeting tumor necrosis factor-α prevents pulmonary arterial hypertension.microRNA-140-5p 通过靶向肿瘤坏死因子-α预防肺动脉高压。
J Cell Physiol. 2019 Jun;234(6):9535-9550. doi: 10.1002/jcp.27642. Epub 2018 Oct 26.
9
Trans-Right-Ventricle and Transpulmonary MicroRNA Gradients in Human Pulmonary Arterial Hypertension.右心室-肺循环 miRNA 梯度在人类肺动脉高压中的变化
Pediatr Crit Care Med. 2020 Apr;21(4):340-349. doi: 10.1097/PCC.0000000000002207.
10
miR-155-5p regulates hypoxia-induced pulmonary artery smooth muscle cell function by targeting PYGL.miR-155-5p 通过靶向 PYGL 调节低氧诱导的肺动脉平滑肌细胞功能。
Bioengineered. 2022 May;13(5):12985-12997. doi: 10.1080/21655979.2022.2079304.
本文引用的文献
1
MicroRNA-212-5p, an anti-proliferative miRNA, attenuates hypoxia and sugen/hypoxia-induced pulmonary hypertension in rodents.微小RNA-212-5p是一种具有抗增殖作用的微小RNA，可减轻啮齿动物中低氧和苏金/低氧诱导的肺动脉高压。
Mol Ther Nucleic Acids. 2022 Jun 22;29:204-216. doi: 10.1016/j.omtn.2022.06.008. eCollection 2022 Sep 13.
2
Pulmonary Arterial Hypertension.肺动脉高压
N Engl J Med. 2021 Dec 16;385(25):2361-2376. doi: 10.1056/NEJMra2000348.
3
The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint.微 RNA 治疗药物发展中的挑战与机遇：多学科视角。
Cells. 2021 Nov 9;10(11):3097. doi: 10.3390/cells10113097.
Zotero 插件